Synnovation Therapeutics
Kevin O'Hayer is a seasoned professional in clinical development, currently serving as the Senior Vice President and Head of Clinical Development at Synnovation Therapeutics since September 2023. Prior experience includes significant roles at Incyte from July 2017 to September 2023, where Kevin held titles such as Associate Vice President, Executive Director of Early Development, and Senior Director. Kevin trained as a Clinical Pharmacology Fellow at Thomas Jefferson University Hospitals from July 2015 to June 2017, specializing in various aspects of pharmacokinetics/pharmacodynamics and clinical trial design. A graduate of the University of Pennsylvania, where Kevin completed a residency in Internal Medicine (July 2012 - June 2014), Kevin obtained a Doctor of Medicine from the University of North Carolina at Chapel Hill School of Medicine (2008 - 2012) and a Doctor of Philosophy in Molecular Cancer Biology from Duke University Graduate School (2002 - 2008). Kevin's academic journey began with a Bachelor's degree in Biology/Biotechnology from the University of Delaware (1998 - 2002).
Synnovation Therapeutics
Synnovation Therapeutics is a precision oncology company focused on small molecule therapies optimized to target key driver mechanisms in cancers.It is dedicated to the discovery and development of therapeutics that can improve the lives of people with cancer. Leveraging its deep expertise in medicinal chemistry, cancer biology, andpatient-focused precision medicine, it builds a diverse pipeline of novel small molecule targeted therapies. It aims to efficiently advance these agents into clinical trials with the goal of transforming cancer patient care.